Holen Sie sich die Stockscreener-App
129.40
1.09%
1.40
Vorhandelsmarkt:
130.02
0.62
+0.48%
Neurocrine Biosciences Inc Aktie (NBIX) Neueste Nachrichten
Guggenheim Maintains Buy Rating on Neurocrine Biosciences Following Investor Meeting - MSN
Neurocrine Biosciences’ SWOT analysis: biotech stock balances Ingrezza success with pipeline potential - Investing.com
Global Tardive Dyskinesia Treatment Market 2025 | - openPR.com
Endometriosis Market on Track for Major Expansion by 2034, - openPR.com
Neurocrine Loses Suit Challenging Hormone Treatment Patent - Law360
Judge Tosses Neurocrine’s Suit Over Spruce Hormone-Drug Patent - Bloomberg Law News
Neurocrine Biosciences names new Chief Information Officer By Investing.com - Investing.com South Africa
Neurocrine Biosciences Appoints Lewis Choi as Chief Information Officer - The Malaysian Reserve
Neurocrine Biosciences (NBIX) Appoints Lewis Choi as CIO | NBIX Stock News - GuruFocus
Neurocrine Biosciences Names Lewis Choi as Chief Information Officer - MarketScreener
Endometriosis Pain Pipeline 2025: Mechanism of Action, Route - openPR.com
Neurocrine Biosciences (NBIX) Appoints Lewis Choi as Chief Information Officer - StreetInsider
Neurocrine Biosciences names new Chief Information Officer - Investing.com
Congenital Adrenal Hyperplasia Market Growth Projections - openPR.com
(NBIX) Technical Data - news.stocktradersdaily.com
Nxera earns $15 million as Neurocrine advances schizophrenia drug - The Pharma Letter
Neurocrine Biosciences Projects Strong Ingrezza Sales For 2025 - Finimize
Nxera Pharma to Receive US$15 Million from Neurocrine - GlobeNewswire
Nxera Pharma to Receive US$15 Million from Neurocrine Biosciences Following Dosing of First Patient in Phase 3 Trial of NBI-1117568 - GlobeNewswire Inc.
Analyst Expectations For Neurocrine Biosciences's Future - Benzinga
Neurocrine Biosciences' Ingrezza to Meet Fiscal 2025 Sales Outlook, RBC Capital Says - marketscreener.com
RBC Capital Reiterates Outperform Rating for Neurocrine Biosciences (NBIX) | NBIX Stock News - GuruFocus
Neurocrine Biosciences Announces Phase 4 KINECT-PRO Data - Nasdaq
[Latest] USA Tardive Dyskinesia Treatment Market: New Drugs, - openPR.com
Neurocrine (NBIX) Reports Positive Results from INGREZZA Study on Tardive Dyskinesia | NBIX Stock News - GuruFocus
Groundbreaking INGREZZA Study Reveals Life-Changing Benefits for Tardive Dyskinesia Patients in Just 4 Weeks - Stock Titan
Neurocrine Biosciences and Carnie Wilson Team Up to Launch ConnectING with Carnie™ Awareness Campaign for People with Tardive Dyskinesia - Quantisnow
Huntington's Disease Society hosts Team Hope Walk in Tulsa Saturday - KTUL
Director Kevin Gorman Sells 9,613 Shares of Neurocrine Biosciences Inc (NBIX) - GuruFocus
Neurocrine Biosciences, Inc. (NBIX)’s M4 Agonist Shows Promise in Schizophrenia Phase 2 Trial, Phase 3 Launched - MSN
In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III - insights.citeline.com
Neurocrine Biosciences director sells shares worth $1.16 million By Investing.com - Investing.com India
Neurocrine Biosciences director sells shares worth $1.16 million - Investing.com
Neurocrine (NBIX) Reports Positive Phase 2 Results for Schizophr - GuruFocus
Taysha’s pivotal trial plans; Keros to stop work on PAH drug, lay off 45% of staff - Endpoints News
Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025 - The Malaysian Reserve
Nxera Pharma Notes Neurocrine Biosciences Presents New - GlobeNewswire
Nxera Pharma Notes Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025 - Yahoo Finance
Neurocrine (NBIX) Reports Positive Phase 2 Results for Schizophrenia Treatment | NBIX Stock News - GuruFocus
Neurocrine reports positive Phase 2 schizophrenia study results - Investing.com
Neurocrine reports positive Phase 2 schizophrenia study results By Investing.com - Investing.com UK
Neurocrine Biosciences’ SWOT analysis: stock’s resilience amid market challenges - Investing.com Australia
How to Take Advantage of moves in (NBIX) - news.stocktradersdaily.com
Insider Decision Making Waves At Neurocrine Biosciences: CHARLES KEVIN GORMAN Exercises Options, Realizing $0 - Nasdaq
Cetera Investment Advisers Purchases 2,593 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - Defense World
Neurocrine at RBC Conference: Growth and Strategic Insights - Investing.com
Transcript : Neurocrine Biosciences, Inc. Presents at RBC Capital Markets Global Healthcare Conference 2025, May-20-2025 11 - marketscreener.com
Tourette Syndrome Treatment Market Detailed Analysis - openPR.com
Neurocrine Biosciences (NBIX) Shares Positive Results from Pedia - GuruFocus
Neurocrine reports quality of life gains in tardive dyskinesia study By Investing.com - Investing.com South Africa
Neurocrine Presents Encouraging New Data From Phase 4 Study Of Ingrezza In Tardive Dyskinesia - Nasdaq
1.48%
0.40%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):